- Report
- March 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- May 2024
- 137 Pages
Global
From €6178EUR$6,499USD£5,190GBP
- Report
- May 2024
- 138 Pages
Global
From €6178EUR$6,499USD£5,190GBP
- Clinical Trials
- December 2024
- 80 Pages
Global
From €1901EUR$2,000USD£1,597GBP
- Drug Pipelines
- March 2025
- 60 Pages
Global
From €1426EUR$1,500USD£1,198GBP
- Report
- June 2024
- 105 Pages
Global
From €14255EUR$14,995USD£11,976GBP
- Report
- March 2025
Global
From €300EUR$338USD£261GBP
- Report
- October 2023
- 190 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- April 2018
- 195 Pages
Global
From €14255EUR$14,995USD£11,976GBP
- Report
- March 2021
- 48 Pages
Global
€20914EUR$22,000USD£17,570GBP
- Report
- August 2022
- 375 Pages
Global
From €2377EUR$2,500USD£1,997GBP
- Report
- August 2022
- 149 Pages
Global
From €1901EUR$2,000USD£1,597GBP
Prolia is a prescription drug used to treat osteoporosis in postmenopausal women. It is a monoclonal antibody that works by inhibiting the activity of a protein called RANKL, which is involved in the breakdown of bones. Prolia is part of a class of drugs known as Endocrine and Metabolic Disorders Drugs, which are used to treat a variety of conditions related to hormones and metabolism. These drugs are used to treat conditions such as diabetes, thyroid disorders, and obesity.
Prolia is approved by the US Food and Drug Administration (FDA) for the treatment of postmenopausal osteoporosis. It is available in both injectable and oral forms. The drug is typically administered once every six months. Common side effects of Prolia include joint pain, muscle pain, and fatigue.
Companies in the Prolia market include Amgen, Inc., Eli Lilly and Company, and Merck & Co., Inc. Show Less Read more